Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Podcasts » Is two better than one? Early optimisation with dual bronchodilation in COPD

International Journal of Chronic Obstructive Pulmonary Disease


Is two better than one? Early optimisation with dual bronchodilation in COPD

Filetype: MP3 - Size: 18.4MB - Duration: 22:21mins

Professor Dave Singh joins Dr Richard Russell to explore the benefits of using dual bronchodilation versus monobronchodilation in patients with COPD.1 They will explain the impact of breathlessness and physical inactivity on patients,2,3 as well as what the clinical guidelines recommend in terms of initial and follow-up treatment for COPD.1,4 A new publication focusing on the long-term effects of pulmonary rehabilitation in elderly patients will be highlighted by Dr Russell,5 followed by a review of the impact of biomass fuel on COPD, a current hot topic on social media.

1 Global Initiative for Chronic Obstructive Lung Disease. Updated 2022. Available here. Last accessed: November 2021;
2 Troosters T, et al. Respir Med 2010;104:1005–1011;
3 Waschki B, et al. Chest 2011;140:331–342;
4 Nici L, et al. Am J Respir Crit Care Med 2020;201:e56–e59;
5 Gephine S, et al. Int J Chron Obstruct Pulmon Dis 2020;15:2505–2514.

Disclosures
Dr Richard Russell
Dr Richard Russell has received speaker fees from AstraZeneca, GlaxoSmithKline, Chiesi and Boehringer Ingelheim. He has also received project grant support from AstraZeneca.

Professor Dave Singh
Professor Dave Singh has received personal fees from Aerogen, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, CSL Behring, EpiEndo, Genentech, GlaxoSmithKline, Glenmark, Gossamer Bio, Kinaset, Menarini, Novartis, Pulmatrix, Sanofi, Teva, Theravance and Verona.

Bios:

Dr Richard Russell
Dr Richard Russell is a Consultant Chest Physician at Lymington New Forest Hospital (UK), as well as a Senior Clinical Researcher at the University of Oxford, and is the founding editor of the International Journal of COPD. He is also the Clinical Lead for Respiratory Medicine, Southeast England, UK, the Director of West Hampshire Integrated Respiratory Service, UK, and an Honorary Senior Lecturer at Imperial College London, UK.

Professor Dave Singh
Dave Singh is Professor of Clinical Pharmacology & Respiratory Medicine at the University of Manchester and supported by the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre (BRC). He graduated in medicine from Cambridge University and then specialised in clinical pharmacology and respiratory medicine. His research interest is the development of new drugs for asthma and COPD. He is the Medical Director of the Medicines Evaluation Unit at the University of Manchester, where he has acted as principal investigator in over 300 clinical trials. He is a member of the GOLD Science Committee, and an editor of the European Respiratory Journal and European Respiratory Review. He is a fellow of the European Respiratory Society and of the British Pharmacology Society, and has over 350 publications.

DOI: 10.2147/PODCAST.COPD.2

Download transcript: here

Back to podcast main page

Published on: 1 December 2021